Background: It has long been debated whether cava anastomosis should be performed with the piggyback technique or cava replacement, with or without veno-venous bypass (VVB), with or without temporary portocaval shunt (PCS) in the setting of liver transplantation.

Objectives: To identify whether different cava anastomotic techniques and other maneuvers benefit the recipient regarding short-term outcomes and to provide international expert panel recommendations.

Data Sources: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.

Methods: A systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel (CRD42021240979).

Results: Of 3205 records screened, 307 publications underwent full-text assessment for eligibility and 47 were included in qualitative synthesis. Four studies were randomized control trials. Eighteen studies were comparative. The remaining 25 were single-center retrospective noncomparative studies.

Conclusion: Based on existing data and expert opinion, the panel cannot recommend one cava reconstruction technique over another, rather the surgical approach should be based on surgeon preference and center dependent, with special consideration toward patient circumstances (Quality of evidence: Low | Grade of Recommendation: Strong). The panel recommends against routine use of vevo-venous bypass (Quality of evidence: Very Low | Grade of Recommendation: Strong) and against the routine use of temporary porto-caval shunt (Quality of evidence: Very Low | Grade of Recommendation: Strong).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078200PMC
http://dx.doi.org/10.1111/ctr.14681DOI Listing

Publication Analysis

Top Keywords

expert panel
12
quality evidence
12
evidence low
12
low grade
12
grade recommendation
12
recommendation strong
12
cava anastomotic
8
anastomotic techniques
8
short-term outcomes
8
systematic review
8

Similar Publications

A cross-sectional online survey was conducted. A high proportion of the Chinese breast cancer (BC) physician respondents (n=77) would prescribe extended adjuvant endocrine therapy (AET) with aromatase inhibitors (AI) beyond 5 years for postmenopausal females with BC, especially those with higher risk. Respondents with ≥15 years of clinical experience were more likely to prescribe a longer duration of AET for low-risk patients.

View Article and Find Full Text PDF

Toward a national framework for the secondary use of health data: an American Medical Informatics Association White Paper.

J Am Med Inform Assoc

March 2007

American Medical Informatics Association, 4915 St. Elmo Avenue, Suite 401, Bethesda, MD 20814, USA.

Secondary use of health data applies personal health information (PHI) for uses outside of direct health care delivery. It includes such activities as analysis, research, quality and safety measurement, public health, payment, provider certification or accreditation, marketing, and other business applications, including strictly commercial activities. Secondary use of health data can enhance health care experiences for individuals, expand knowledge about disease and appropriate treatments, strengthen understanding about effectiveness and efficiency of health care systems, support public health and security goals, and aid businesses in meeting customers' needs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!